JP2018514549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514549A5 JP2018514549A5 JP2017556627A JP2017556627A JP2018514549A5 JP 2018514549 A5 JP2018514549 A5 JP 2018514549A5 JP 2017556627 A JP2017556627 A JP 2017556627A JP 2017556627 A JP2017556627 A JP 2017556627A JP 2018514549 A5 JP2018514549 A5 JP 2018514549A5
- Authority
- JP
- Japan
- Prior art keywords
- agent according
- cancer
- drug
- rad1901
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- SIFNOOUKXBRGGB-AREMUKBSSA-N (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1=CC(CCNCC)=CC=C1CN(CC)C1=CC(OC)=CC=C1[C@H]1CC2=CC=C(O)C=C2CC1 SIFNOOUKXBRGGB-AREMUKBSSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- -1 DDR2 Proteins 0.000 claims 5
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229960005167 everolimus Drugs 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims 4
- 102100038595 Estrogen receptor Human genes 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 229940046836 anti-estrogen Drugs 0.000 claims 3
- 230000001833 anti-estrogenic effect Effects 0.000 claims 3
- 239000003886 aromatase inhibitor Substances 0.000 claims 3
- 239000000328 estrogen antagonist Substances 0.000 claims 3
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 claims 2
- 102100040859 Fizzy-related protein homolog Human genes 0.000 claims 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- XGFHYCAZOCBCRQ-FBHGDYMESA-N (6r)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol;dihydrochloride Chemical group Cl.Cl.C1=CC(CCNCC)=CC=C1CN(CC)C1=CC(OC)=CC=C1[C@H]1CC2=CC=C(O)C=C2CC1 XGFHYCAZOCBCRQ-FBHGDYMESA-N 0.000 claims 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 1
- 102100034580 AT-rich interactive domain-containing protein 1A Human genes 0.000 claims 1
- 102000000872 ATM Human genes 0.000 claims 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims 1
- 102000004000 Aurora Kinase A Human genes 0.000 claims 1
- 108090000461 Aurora Kinase A Proteins 0.000 claims 1
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 108700020462 BRCA2 Proteins 0.000 claims 1
- 102000052609 BRCA2 Human genes 0.000 claims 1
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 claims 1
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 claims 1
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 102100026008 Breakpoint cluster region protein Human genes 0.000 claims 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims 1
- 102100028914 Catenin beta-1 Human genes 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 claims 1
- 108010058546 Cyclin D1 Proteins 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 102000009512 Cyclin-Dependent Kinase Inhibitor p15 Human genes 0.000 claims 1
- 108010009356 Cyclin-Dependent Kinase Inhibitor p15 Proteins 0.000 claims 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 claims 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 claims 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 claims 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 claims 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 1
- 101150097734 EPHB2 gene Proteins 0.000 claims 1
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 claims 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 claims 1
- 101710105178 F-box/WD repeat-containing protein 7 Proteins 0.000 claims 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims 1
- 102100021066 Fibroblast growth factor receptor substrate 2 Human genes 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims 1
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 claims 1
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 claims 1
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 claims 1
- 102100029974 GTPase HRas Human genes 0.000 claims 1
- 102100039788 GTPase NRas Human genes 0.000 claims 1
- 102100031561 Hamartin Human genes 0.000 claims 1
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 claims 1
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims 1
- 101000924266 Homo sapiens AT-rich interactive domain-containing protein 1A Proteins 0.000 claims 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 1
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 claims 1
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 claims 1
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 claims 1
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 claims 1
- 101001060267 Homo sapiens Fibroblast growth factor 5 Proteins 0.000 claims 1
- 101000818410 Homo sapiens Fibroblast growth factor receptor substrate 2 Proteins 0.000 claims 1
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 claims 1
- 101000738559 Homo sapiens G1/S-specific cyclin-D3 Proteins 0.000 claims 1
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 claims 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 1
- 101000795643 Homo sapiens Hamartin Proteins 0.000 claims 1
- 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 claims 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 1
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims 1
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 claims 1
- 101001025967 Homo sapiens Lysine-specific demethylase 6A Proteins 0.000 claims 1
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 claims 1
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 claims 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 1
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 claims 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 claims 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims 1
- 101100087590 Homo sapiens RICTOR gene Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 claims 1
- 101001112293 Homo sapiens Retinoic acid receptor alpha Proteins 0.000 claims 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 1
- 101000904150 Homo sapiens Transcription factor E2F3 Proteins 0.000 claims 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 claims 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims 1
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims 1
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 claims 1
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 claims 1
- 102100037462 Lysine-specific demethylase 6A Human genes 0.000 claims 1
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 claims 1
- 102000017274 MDM4 Human genes 0.000 claims 1
- 108050005300 MDM4 Proteins 0.000 claims 1
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 claims 1
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 claims 1
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 1
- 101150097381 Mtor gene Proteins 0.000 claims 1
- 102100027096 Nucleotide exchange factor SIL1 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 claims 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 1
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 claims 1
- 102100026375 Protein PML Human genes 0.000 claims 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims 1
- 102000004229 RNA-binding protein EWS Human genes 0.000 claims 1
- 108090000740 RNA-binding protein EWS Proteins 0.000 claims 1
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 claims 1
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 claims 1
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 claims 1
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 claims 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims 1
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims 1
- 101710145783 TATA-box-binding protein Proteins 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 1
- 102100024027 Transcription factor E2F3 Human genes 0.000 claims 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims 1
- 102100031638 Tuberin Human genes 0.000 claims 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 claims 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000002511 pituitary cancer Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- OEPGMBNGBMZEQC-ZCJYOONXSA-N CCNCCc1ccc(CN(CC)c2c([C@H](CC3)CC4C3=CC(O)=CC4)c(C)cc(OC)c2)cc1 Chemical compound CCNCCc1ccc(CN(CC)c2c([C@H](CC3)CC4C3=CC(O)=CC4)c(C)cc(OC)c2)cc1 OEPGMBNGBMZEQC-ZCJYOONXSA-N 0.000 description 1
Applications Claiming Priority (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154699P | 2015-04-29 | 2015-04-29 | |
| US62/154,699 | 2015-04-29 | ||
| US201562155451P | 2015-04-30 | 2015-04-30 | |
| US62/155,451 | 2015-04-30 | ||
| US201562158469P | 2015-05-07 | 2015-05-07 | |
| US62/158,469 | 2015-05-07 | ||
| US201562192944P | 2015-07-15 | 2015-07-15 | |
| US201562192940P | 2015-07-15 | 2015-07-15 | |
| US62/192,944 | 2015-07-15 | ||
| US62/192,940 | 2015-07-15 | ||
| US201562252085P | 2015-11-06 | 2015-11-06 | |
| US62/252,085 | 2015-11-06 | ||
| US201562252916P | 2015-11-09 | 2015-11-09 | |
| US62/252,916 | 2015-11-09 | ||
| US201562265696P | 2015-12-10 | 2015-12-10 | |
| US201562265663P | 2015-12-10 | 2015-12-10 | |
| US201562265658P | 2015-12-10 | 2015-12-10 | |
| US201562265774P | 2015-12-10 | 2015-12-10 | |
| US62/265,774 | 2015-12-10 | ||
| US62/265,663 | 2015-12-10 | ||
| US62/265,658 | 2015-12-10 | ||
| US62/265,696 | 2015-12-10 | ||
| US201662323572P | 2016-04-15 | 2016-04-15 | |
| US201662323576P | 2016-04-15 | 2016-04-15 | |
| US62/323,572 | 2016-04-15 | ||
| US62/323,576 | 2016-04-15 | ||
| PCT/US2016/030316 WO2016176664A1 (en) | 2015-04-29 | 2016-04-29 | Methods for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514549A JP2018514549A (ja) | 2018-06-07 |
| JP2018514549A5 true JP2018514549A5 (enExample) | 2019-05-30 |
| JP7019422B2 JP7019422B2 (ja) | 2022-02-15 |
Family
ID=57198783
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509732A Active JP6926066B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
| JP2018509731A Active JP6926065B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
| JP2017556627A Active JP7019422B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
| JP2021052305A Active JP7146992B2 (ja) | 2015-04-29 | 2021-03-25 | 癌を治療するための方法 |
| JP2021073337A Active JP7262508B2 (ja) | 2015-04-29 | 2021-04-23 | 癌を治療するための方法 |
| JP2022150560A Active JP7516472B2 (ja) | 2015-04-29 | 2022-09-21 | 癌を治療するための方法 |
| JP2023009598A Active JP7696378B2 (ja) | 2015-04-29 | 2023-01-25 | 癌を治療するための方法 |
| JP2024107407A Active JP7745708B2 (ja) | 2015-04-29 | 2024-07-03 | 癌を治療するための方法 |
| JP2025153179A Pending JP2025170141A (ja) | 2015-04-29 | 2025-09-16 | 癌を治療するための方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509732A Active JP6926066B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
| JP2018509731A Active JP6926065B2 (ja) | 2015-04-29 | 2016-04-29 | 癌を治療するための方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021052305A Active JP7146992B2 (ja) | 2015-04-29 | 2021-03-25 | 癌を治療するための方法 |
| JP2021073337A Active JP7262508B2 (ja) | 2015-04-29 | 2021-04-23 | 癌を治療するための方法 |
| JP2022150560A Active JP7516472B2 (ja) | 2015-04-29 | 2022-09-21 | 癌を治療するための方法 |
| JP2023009598A Active JP7696378B2 (ja) | 2015-04-29 | 2023-01-25 | 癌を治療するための方法 |
| JP2024107407A Active JP7745708B2 (ja) | 2015-04-29 | 2024-07-03 | 癌を治療するための方法 |
| JP2025153179A Pending JP2025170141A (ja) | 2015-04-29 | 2025-09-16 | 癌を治療するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (12) | US20180214393A1 (enExample) |
| EP (4) | EP3288383A4 (enExample) |
| JP (9) | JP6926066B2 (enExample) |
| KR (9) | KR102676629B1 (enExample) |
| CN (5) | CN113288887A (enExample) |
| AU (3) | AU2016256469B2 (enExample) |
| BR (3) | BR112017023233A2 (enExample) |
| CA (3) | CA2984357A1 (enExample) |
| HK (3) | HK1251407A1 (enExample) |
| IL (10) | IL297369B2 (enExample) |
| MX (6) | MX384605B (enExample) |
| RU (3) | RU2745678C2 (enExample) |
| SG (4) | SG11201708861VA (enExample) |
| WO (3) | WO2016176665A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| PL3122426T3 (pl) | 2014-03-28 | 2023-05-15 | Duke University | Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego |
| WO2016176665A1 (en) | 2015-04-29 | 2016-11-03 | Radius Health, Inc. | Methods of treating cancer |
| UY37124A (es) | 2016-02-15 | 2017-09-29 | Sanofi Sa | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| SG10202104282SA (en) * | 2016-09-27 | 2021-06-29 | Radius Pharmaceuticals Inc | Methods for treating ovarian cancer |
| CN112933082A (zh) * | 2016-10-11 | 2021-06-11 | 杜克大学 | Er+乳腺癌的拉索昔芬治疗 |
| RU2742278C2 (ru) | 2016-11-17 | 2021-02-04 | Санофи | Новые соединения замещенного n-(3-фторпропил)пирролидина, способы их получения и их терапевтическое применение |
| EP4374925A3 (en) * | 2017-01-05 | 2025-01-15 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
| BR112019019261A2 (pt) * | 2017-03-16 | 2020-06-16 | Eisai R & D Management Co., Ltd. | Terapias de combinação para o tratamento de câncer de mama |
| US12012421B2 (en) | 2017-07-07 | 2024-06-18 | Hoffmann-La Roche Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| EP3434272A1 (en) * | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| WO2019097426A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Pharmaceutical combination comprising lsz102 and ribociclib |
| US12012420B2 (en) | 2017-11-21 | 2024-06-18 | Hoffmann-La Roche, Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| US10695333B2 (en) | 2017-12-01 | 2020-06-30 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and alpelisib |
| US11497730B2 (en) | 2018-04-10 | 2022-11-15 | Duke University | Lasofoxifene treatment of breast cancer |
| CN110585429B (zh) * | 2018-06-12 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途 |
| CN112423844B (zh) * | 2018-07-04 | 2024-08-13 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
| TW202026280A (zh) | 2018-09-07 | 2020-07-16 | 法商賽諾菲公司 | 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧基苯基]-8,9-二氫-7h-苯並[7]輪烯-2-甲酸甲酯的鹽及其製備方法 |
| UA129403C2 (uk) * | 2018-11-30 | 2025-04-16 | Радіус Фармасеутікалс, Інк. | Елацестрант в комбінації з абемациклібом у жінок з раком молочної залози |
| PH12021551319A1 (en) * | 2018-12-06 | 2022-05-16 | Radius Pharmaceuticals Inc | Methods for treating cancer resistant to cdk4/6 inhibitors |
| MA54393A (fr) * | 2018-12-06 | 2021-10-13 | Radius Pharmaceuticals Inc | Méthodes de traitement du cancer chez des modèles présentant des mutations esr1 |
| JP7590084B2 (ja) * | 2018-12-12 | 2024-11-26 | ケモセントリックス，インコーポレイティド | 癌治療のためのｃｘｃｒ７阻害剤 |
| CN119390714A (zh) | 2019-02-12 | 2025-02-07 | 雷迪厄斯制药公司 | 方法和化合物 |
| CA3146346A1 (en) * | 2019-05-09 | 2020-11-12 | Sanofi | 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients |
| CA3144791A1 (en) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| KR102341347B1 (ko) * | 2019-11-28 | 2021-12-20 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| CN115175679A (zh) * | 2020-03-06 | 2022-10-11 | 奥列马制药公司 | 治疗雌激素受体相关疾病的方法 |
| IL297216A (en) * | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Dosage regimen for the treatment of cancer |
| EP4149476A1 (en) | 2020-05-12 | 2023-03-22 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor |
| WO2022029799A1 (en) * | 2020-08-05 | 2022-02-10 | Aizant Drug Research Solutions Private Limited | Solid dosage forms of palbociclib |
| CA3202592A1 (en) * | 2020-12-14 | 2022-06-23 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| AU2022222660A1 (en) * | 2021-02-16 | 2023-07-27 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib |
| CN113662942B (zh) * | 2021-08-19 | 2023-02-07 | 中国人民解放军陆军军医大学第一附属医院 | 药物组合物及其在smo突变性髓母细胞瘤中的应用 |
| WO2023064519A1 (en) | 2021-10-14 | 2023-04-20 | Teva Pharmaceuticals International Gmbh | Solid state forms of elacestrant and processes for preparation thereof |
| DE102021130035A1 (de) | 2021-11-17 | 2023-05-17 | USound GmbH | MEMS-Schallwandler mit einer gekrümmten Kontur eines Kragarmelements |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| WO2024104268A1 (zh) * | 2022-11-15 | 2024-05-23 | 苏州科睿思制药有限公司 | 艾拉司群二盐酸盐的共晶及其制备方法和用途 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
| EP4574811A1 (en) | 2023-12-22 | 2025-06-25 | Sandoz Ag | Crystalline forms of elacestrant dihydrochloride |
| WO2025158416A1 (en) | 2024-01-25 | 2025-07-31 | Assia Chemical Industries Ltd. | Solid state forms of elacestrant and processes for preparation thereof |
Family Cites Families (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3939346A1 (de) | 1989-11-29 | 1991-06-06 | Behringwerke Ag | Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide |
| US5589452A (en) | 1992-07-14 | 1996-12-31 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| US5821225A (en) | 1992-07-14 | 1998-10-13 | Syntex (U.S.A.) Inc. | Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp |
| US5977070A (en) | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
| DE19517430A1 (de) | 1995-05-12 | 1996-11-14 | Boehringer Mannheim Gmbh | Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode |
| IT1285405B1 (it) | 1995-06-06 | 1998-06-03 | Alza Corp | Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto. |
| US5723577A (en) | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
| US7410948B2 (en) | 1995-07-13 | 2008-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogs of parathyroid hormone |
| US5955574A (en) | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
| US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
| US5969095A (en) | 1995-07-13 | 1999-10-19 | Biomeasure, Inc. | Analogs of parathyroid hormone |
| DE19538687A1 (de) | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon |
| DE19539574A1 (de) | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
| TWI240627B (en) | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| TW505654B (en) | 1996-07-30 | 2002-10-11 | Hoffmann La Roche | Synthesis of analogs of PTH and PTHrP |
| DE951551T1 (de) | 1996-12-23 | 2000-09-14 | Immunex Corp., Seattle | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
| US6136784A (en) | 1997-01-08 | 2000-10-24 | Amylin Pharmaceuticals, Inc. | Amylin agonist pharmaceutical compositions containing insulin |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| CA2302255C (en) | 1997-09-09 | 2011-11-08 | F. Hoffmann-La Roche Ag | Fracture healing using pthrp analogs |
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| MY120063A (en) | 1997-12-09 | 2005-08-30 | Lilly Co Eli | Stabilized teriparatide solutions |
| WO1999029364A1 (en) | 1997-12-11 | 1999-06-17 | Alza Corporation | Device for enhancing transdermal agent flux |
| EP1037686B1 (en) | 1997-12-11 | 2005-08-17 | Alza Corporation | Device for enhancing transdermal agent flux |
| EP0922467A3 (en) | 1997-12-12 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Iontophoretic drug delivery |
| JP4154017B2 (ja) | 1997-12-30 | 2008-09-24 | 久光製薬株式会社 | イオントフォレーシス装置および薬物ユニット |
| US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
| SE9801495D0 (sv) | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulationa |
| US6316410B1 (en) | 1999-09-22 | 2001-11-13 | National Research Council Of Canada | Parathyroid hormone analogues for the treatment of osteoporosis |
| WO2001036039A2 (en) | 1999-11-17 | 2001-05-25 | Novartis Ag | Iontophoretic transdermal delivery of peptides |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| US20010044431A1 (en) | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| US20050124537A1 (en) | 2000-04-27 | 2005-06-09 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| AU8206401A (en) | 2000-08-03 | 2002-02-18 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| IL154408A0 (en) | 2000-08-23 | 2003-09-17 | Akzo Nobel Nv | 10-ARYL-11-H BENZO [b] FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE |
| US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| RU2282468C2 (ru) | 2000-10-26 | 2006-08-27 | Алза Корпорейшн | Устройство для трансдермальной доставки лекарственных средств, имеющее микровыступы с покрытием |
| CA2444883A1 (en) | 2001-04-20 | 2002-10-31 | Alza Corporation | Microprojection array having a beneficial agent containing coating |
| DK2270052T3 (en) | 2001-06-26 | 2018-07-02 | Amgen Inc | Antibodies to OPGL |
| US6881203B2 (en) | 2001-09-05 | 2005-04-19 | 3M Innovative Properties Company | Microneedle arrays and methods of manufacturing the same |
| US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
| DE60223844T2 (de) | 2001-12-20 | 2008-08-28 | Alza Corp., Mountain View | Mikrovorsprünge zum durchstechen der haut mit stechtiefensteuerung |
| EP1465619A1 (en) | 2002-01-14 | 2004-10-13 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
| WO2003068805A2 (en) | 2002-02-14 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Formulation strategies in stabilizing peptides in organic solvents and in dried states |
| EP1513547A4 (en) | 2002-05-23 | 2009-11-04 | Michael F Holick | USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY |
| TW200307553A (en) | 2002-05-24 | 2003-12-16 | Akzo Nobel Nv | Treatment of post-menopausal complaints in breast cancer patients |
| US7799757B2 (en) | 2002-06-13 | 2010-09-21 | Michael Chorev | Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents |
| WO2004007520A2 (en) | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
| MXPA05000597A (es) | 2002-07-19 | 2005-04-28 | 3M Innovative Properties Co | Dispositivos de microaguja y aparatos de administracion por microaguja. |
| MXPA05003797A (es) | 2002-10-14 | 2005-06-08 | Novo Nordisk As | Variantes de peptido-2 tipo glucagon. |
| US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
| US7662404B2 (en) | 2002-10-31 | 2010-02-16 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides |
| IL152574A (en) | 2002-10-31 | 2009-09-22 | Transpharma Medical Ltd | A system for passing through the skin of dry items or dried medicines |
| US8133505B2 (en) | 2002-10-31 | 2012-03-13 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| US7383084B2 (en) | 2002-10-31 | 2008-06-03 | Transpharma Medical Ltd. | Transdermal delivery system for dried particulate or lyophilized medications |
| EP1567178A4 (en) | 2002-11-01 | 2009-07-15 | Amgen Inc | MODULATORS OF RECEPTORS FOR NEUTRAL THERAPY HORMONE AND SIDE-HORSE HORMONE-RELATED PROTEINS |
| AU2003292625B2 (en) * | 2002-12-26 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Selective estrogen receptor modulators |
| EP1654221A2 (en) | 2003-06-10 | 2006-05-10 | Smithkline Beecham Corporation | Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
| JP2007505164A (ja) | 2003-06-10 | 2007-03-08 | スミスクライン ビーチャム コーポレーション | アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類 |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| KR20060038407A (ko) | 2003-06-30 | 2006-05-03 | 알자 코포레이션 | 비휘발성 반대이온을 포함하는 코팅된 미세돌출부용 제제 |
| KR20060029162A (ko) | 2003-06-30 | 2006-04-04 | 알자 코포레이션 | 피부 피어싱 미세돌출부를 코팅하는 방법 |
| WO2005014034A1 (en) | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
| US7141544B2 (en) | 2003-10-10 | 2006-11-28 | Baxter International, Inc. | Stabilization of pharmaceutical protein formulations with small peptides |
| GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| BRPI0415967A (pt) | 2003-10-28 | 2007-01-23 | Alza Corp | aplicação de conjugados de polìmero de peptìdeos e proteìnas terapêuticos através de microprojeções revestidas |
| KR20060099523A (ko) | 2003-10-31 | 2006-09-19 | 알자 코포레이션 | 미세 돌출부 어레이를 위한 자가 작동 어플리케이터 |
| AU2004292954A1 (en) | 2003-11-13 | 2005-06-09 | Alza Corporation | Composition and apparatus for transdermal delivery |
| US20070129409A1 (en) | 2003-11-20 | 2007-06-07 | Lain-Yen Hu | Androgen receptor modulators |
| KR20070011252A (ko) | 2003-11-21 | 2007-01-24 | 알자 코포레이션 | 초음파 보조 경피 백신전달방법 및 시스템 |
| IL159273A0 (en) | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
| WO2005060956A1 (en) | 2003-12-12 | 2005-07-07 | University Of Maryland, Baltimore | IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN |
| WO2005066194A1 (en) | 2004-01-07 | 2005-07-21 | Endorecherche, Inc. | Helix 12 directed steroidal pharmaceutical products |
| IL160033A0 (en) | 2004-01-25 | 2004-06-20 | Transpharma Medical Ltd | Transdermal delivery system for polynucleotides |
| TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
| GB0405033D0 (en) | 2004-03-05 | 2004-04-07 | Karobio Ab | Novel pharmaceutical compositions |
| CA2562132A1 (en) | 2004-04-08 | 2005-10-27 | Merck & Co., Inc. | 17 beta-acetamide-4-azasteroids as androgen receptor modulators |
| CA2567056A1 (en) | 2004-05-10 | 2005-12-08 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of parathyroid hormone |
| MXPA06013115A (es) | 2004-05-11 | 2007-02-28 | Pfizer Prod Inc | Derivados de benzonitrilo para tratar la fragilidad musculoesqueletica. |
| EP1744683B1 (en) | 2004-05-13 | 2016-03-16 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| US7906137B2 (en) | 2004-05-21 | 2011-03-15 | Mediplex Corporation, Korea | Delivery agents for enhancing mucosal absorption of therapeutic agents |
| EP1765406A4 (en) | 2004-05-21 | 2012-11-28 | Mediplex Corp | ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS |
| US20090069226A1 (en) | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| AU2005310238A1 (en) | 2004-10-29 | 2006-06-08 | Merck Sharp & Dohme Corp. | N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators |
| US8057842B2 (en) | 2004-11-18 | 2011-11-15 | 3M Innovative Properties Company | Method of contact coating a microneedle array |
| CN101102809B (zh) | 2004-11-18 | 2010-05-26 | 3M创新有限公司 | 涂敷微针阵列的遮蔽方法 |
| JP2008520331A (ja) | 2004-11-18 | 2008-06-19 | トランスファーマ メディカル リミテッド | 薬剤の経皮的送達のためのマイクロチャネル形成とイオントフォレーシスの組合せ |
| US20060188555A1 (en) | 2005-01-21 | 2006-08-24 | Micheal Cormier | Therapeutic peptide formulations with improved stability |
| WO2006113552A2 (en) | 2005-04-15 | 2006-10-26 | Smithkline Beecham Corporation | Cyanoarylamines |
| KR100700869B1 (ko) | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물 |
| WO2006133216A2 (en) | 2005-06-06 | 2006-12-14 | Smithkline Beecham Corporation | 4-substituted arylamine derivatives and their use in pharmaceutical compositions |
| US20090227571A1 (en) | 2005-07-01 | 2009-09-10 | Ligand Pharmaceuticals Incorporated | Androgen Receptor Modulator Compounds and Methods |
| US20070021216A1 (en) | 2005-07-19 | 2007-01-25 | Sony Ericsson Mobile Communications Ab | Seamless gaming method and apparatus |
| JP2008303145A (ja) | 2005-09-22 | 2008-12-18 | Takeda Chem Ind Ltd | Ｇｒｋ阻害剤からなる強心薬 |
| WO2007061781A1 (en) | 2005-11-18 | 2007-05-31 | 3M Innovative Properties Company | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
| ES2551305T3 (es) | 2005-12-28 | 2015-11-17 | Alza Corporation | Formulaciones terapéuticas estables |
| CA2680690A1 (en) | 2006-03-15 | 2007-09-20 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia |
| EP2024078A2 (en) | 2006-04-20 | 2009-02-18 | Velocys, Inc. | Process for treating and/or forming a non-newtonian fluid using microchannel process technology |
| EA200802166A1 (ru) | 2006-04-20 | 2009-06-30 | Эмджен Инк. | Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью |
| US9119945B2 (en) | 2006-04-20 | 2015-09-01 | 3M Innovative Properties Company | Device for applying a microneedle array |
| CN101085743B (zh) | 2006-06-06 | 2012-02-15 | 浙江大德药业集团有限公司 | 含氟烷氧基康普立停衍生物及制法和用途 |
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| WO2008008433A2 (en) | 2006-07-12 | 2008-01-17 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| CN101528214B (zh) | 2006-08-24 | 2013-06-05 | 田纳西大学研究基金会 | 取代的n-酰基苯胺及其使用方法 |
| EA015644B1 (ru) | 2006-08-25 | 2011-10-31 | Арес Трейдинг С.А. | Способ лечения заболеваний хряща |
| CN1927815A (zh) | 2006-09-25 | 2007-03-14 | 天津理工大学 | 邻苄胺基苯基醚化合物、化合物的衍生物及其制备方法与用途 |
| US7803770B2 (en) | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| SI2957278T1 (sl) | 2006-10-03 | 2017-09-29 | Radius Health, Inc. | Stabilni sestavek, ki obsega PTHrP, in njegova uporaba |
| WO2008044033A1 (en) | 2006-10-11 | 2008-04-17 | Astrazeneca Ab | Amide derivatives |
| ES2473620T3 (es) | 2007-02-06 | 2014-07-07 | Hisamitsu Pharmaceutical Co., Inc. | Dispositivo de microagujas para el diagnóstico de una alergia |
| WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
| WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
| WO2008130587A2 (en) | 2007-04-16 | 2008-10-30 | Corium International, Inc. | Solvent-cast microneedle arrays containing active |
| GB0707938D0 (en) | 2007-04-25 | 2007-05-30 | Univ Strathclyde | Precipitation stabilising compositions |
| WO2008145125A1 (en) * | 2007-05-31 | 2008-12-04 | Dako Denmark A/S | Methods for utilizing esr copy number changes in breast cancer treatments and prognoses |
| US20110009387A1 (en) | 2007-06-12 | 2011-01-13 | Andrea Dawn Basso-Porcaro | Histone h2ax (hh2ax) biomarker for fti sensitivity |
| US8450481B2 (en) | 2007-06-14 | 2013-05-28 | The Regents Of The University Of California | Compounds for inhibiting protein aggregation, and methods for making and using them |
| US20120150023A1 (en) | 2007-08-06 | 2012-06-14 | Kaspar Roger L | Microneedle arrays for active agent delivery |
| ES2612061T3 (es) | 2007-09-28 | 2017-05-11 | The Queen's University Of Belfast | Dispositivo y método de suministro |
| US20090117158A1 (en) | 2007-10-23 | 2009-05-07 | Mahmoud Ameri | Transdermal sustained release drug delivery |
| EP2052736A1 (en) | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
| WO2009065126A2 (en) | 2007-11-16 | 2009-05-22 | Boston Protein Solutions | Excipients for protein stabilization |
| WO2009133861A1 (ja) | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
| WO2009137104A1 (en) * | 2008-05-09 | 2009-11-12 | Radius Health, Inc. | Combination therapy for breastcancer comprising an antiestrogenic agent |
| WO2010022176A1 (en) | 2008-08-19 | 2010-02-25 | Ferring International Center S.A. | Methods of treatment for skeletal conditons |
| EP2349200A1 (en) | 2008-10-15 | 2011-08-03 | Intarcia Therapeutics, Inc | Highly concentrated drug particles, formulations, suspensions and uses thereof |
| KR101668502B1 (ko) | 2008-11-04 | 2016-10-21 | 아스카 세이야쿠 가부시키가이샤 | 난포자극호르몬 함유 수성 조성물 |
| EP2355887B1 (en) | 2008-11-18 | 2017-08-02 | 3M Innovative Properties Company | Hollow microneedle array |
| JP5902390B2 (ja) | 2008-12-26 | 2016-04-13 | 久光製薬株式会社 | マイクロニードルデバイス |
| US20100203014A1 (en) | 2009-02-04 | 2010-08-12 | Aegis Therapeutics Llc | Zwitterionic buffered acidic peptide and protein formulations |
| US20100226966A1 (en) | 2009-03-03 | 2010-09-09 | Daddona Peter E | Method for transdermal controlled release drug delivery |
| WO2010118287A1 (en) | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| US20110006458A1 (en) | 2009-04-24 | 2011-01-13 | Corium International, Inc. | Methods for manufacturing microprojection arrays |
| JP5702384B2 (ja) | 2009-07-31 | 2015-04-15 | スリーエム イノベイティブ プロパティズ カンパニー | 中空マイクロニードルアレイ |
| EP2496262A2 (en) | 2009-11-02 | 2012-09-12 | Université de Genève | Stabilized protein formulations and use thereof |
| US20110172609A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Microneedle component assembly for drug delivery device |
| CN101912600B (zh) | 2010-01-11 | 2014-01-29 | 杨国汉 | 改善胰岛素在溶液中稳定性的方法 |
| IE20100174A1 (en) | 2010-03-25 | 2012-02-29 | Trinity College Dublin | Transdermal administration of peptides |
| EP2566501B1 (en) | 2010-05-04 | 2019-03-13 | Corium International, Inc. | Method and device for transdermal delivery of parathyroid hormone using a microprojection array |
| EP2575845B1 (en) | 2010-05-28 | 2017-02-15 | 3M Innovative Properties Company | Aqueous formulations for coating microneedle arrays |
| KR20140089402A (ko) * | 2010-06-16 | 2014-07-14 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
| WO2012075375A1 (en) | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of parathyroid hormones by microinjection systems |
| AU2012223279A1 (en) | 2011-03-01 | 2013-09-26 | Sloan-Kettering Institute For Cancer Research | Parathyroid hormone analogs, compositions and uses thereof |
| JP6033280B2 (ja) | 2011-04-22 | 2016-11-30 | ラジウス ヘルス，インコーポレイテッド | ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法 |
| WO2013082418A1 (en) | 2011-11-30 | 2013-06-06 | 3M Innovative Properties Company | Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same |
| GB201217439D0 (en) | 2012-09-28 | 2012-11-14 | Topotarget As | Combination therapy |
| WO2014203129A1 (en) * | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| CN104436194B (zh) | 2013-09-18 | 2018-03-30 | 北京大学 | 具有协同增效作用的抗癌组合物 |
| EP3099305B1 (en) * | 2014-01-27 | 2025-11-19 | Dna Seq 2, Inc. | Methods and systems for determination of an effective therapeutic regimen and drug discovery |
| SG11201607334YA (en) | 2014-03-13 | 2016-10-28 | Hoffmann La Roche | Therapeutic combinations with estrogen receptor modulators |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| PL3122426T3 (pl) * | 2014-03-28 | 2023-05-15 | Duke University | Leczenie raka sutka z zastosowaniem selektywnych modulatorów receptora estrogenowego |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
| AR104068A1 (es) * | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
| WO2016176665A1 (en) | 2015-04-29 | 2016-11-03 | Radius Health, Inc. | Methods of treating cancer |
-
2016
- 2016-04-29 WO PCT/US2016/030317 patent/WO2016176665A1/en not_active Ceased
- 2016-04-29 RU RU2017140676A patent/RU2745678C2/ru active
- 2016-04-29 KR KR1020177034603A patent/KR102676629B1/ko active Active
- 2016-04-29 KR KR1020247022060A patent/KR102871388B1/ko active Active
- 2016-04-29 IL IL297369A patent/IL297369B2/en unknown
- 2016-04-29 CN CN202110579478.4A patent/CN113288887A/zh active Pending
- 2016-04-29 CA CA2984357A patent/CA2984357A1/en active Pending
- 2016-04-29 CN CN201680038908.9A patent/CN108135177B/zh active Active
- 2016-04-29 KR KR1020257033321A patent/KR20250152679A/ko active Pending
- 2016-04-29 EP EP16787291.0A patent/EP3288383A4/en active Pending
- 2016-04-29 HK HK18110955.2A patent/HK1251407A1/zh unknown
- 2016-04-29 KR KR1020257033320A patent/KR20250153309A/ko active Pending
- 2016-04-29 MX MX2017013802A patent/MX384605B/es unknown
- 2016-04-29 IL IL319266A patent/IL319266A/en unknown
- 2016-04-29 BR BR112017023233-2A patent/BR112017023233A2/en not_active Application Discontinuation
- 2016-04-29 SG SG11201708861VA patent/SG11201708861VA/en unknown
- 2016-04-29 EP EP16787289.4A patent/EP3288382A4/en active Pending
- 2016-04-29 SG SG10202104177VA patent/SG10202104177VA/en unknown
- 2016-04-29 KR KR1020247019989A patent/KR102871408B1/ko active Active
- 2016-04-29 IL IL255148A patent/IL255148B2/en unknown
- 2016-04-29 EP EP22155988.3A patent/EP4039253A1/en active Pending
- 2016-04-29 HK HK18110957.0A patent/HK1251409A1/zh unknown
- 2016-04-29 IL IL255261A patent/IL255261B2/en unknown
- 2016-04-29 WO PCT/US2016/030316 patent/WO2016176664A1/en not_active Ceased
- 2016-04-29 AU AU2016256469A patent/AU2016256469B2/en active Active
- 2016-04-29 SG SG11201708858WA patent/SG11201708858WA/en unknown
- 2016-04-29 CA CA2984195A patent/CA2984195C/en active Active
- 2016-04-29 BR BR112017023228-6A patent/BR112017023228A2/en not_active Application Discontinuation
- 2016-04-29 MX MX2017013794A patent/MX394676B/es unknown
- 2016-04-29 RU RU2017140674A patent/RU2737496C2/ru active
- 2016-04-29 WO PCT/US2016/030321 patent/WO2016176666A1/en not_active Ceased
- 2016-04-29 IL IL310069A patent/IL310069B2/en unknown
- 2016-04-29 MX MX2017013801A patent/MX384908B/es unknown
- 2016-04-29 RU RU2017140675A patent/RU2747228C2/ru active
- 2016-04-29 JP JP2018509732A patent/JP6926066B2/ja active Active
- 2016-04-29 KR KR1020247019929A patent/KR102871380B1/ko active Active
- 2016-04-29 CN CN202110933929.XA patent/CN113750091B/zh active Active
- 2016-04-29 KR KR1020177034606A patent/KR102682763B1/ko active Active
- 2016-04-29 SG SG11201708860SA patent/SG11201708860SA/en unknown
- 2016-04-29 KR KR1020257033319A patent/KR20250152678A/ko active Pending
- 2016-04-29 HK HK18110956.1A patent/HK1251408A1/zh unknown
- 2016-04-29 AU AU2016256470A patent/AU2016256470B2/en active Active
- 2016-04-29 AU AU2016256471A patent/AU2016256471B2/en active Active
- 2016-04-29 IL IL255189A patent/IL255189B2/en unknown
- 2016-04-29 JP JP2018509731A patent/JP6926065B2/ja active Active
- 2016-04-29 CN CN201680038907.4A patent/CN108024540B/zh active Active
- 2016-04-29 KR KR1020177034608A patent/KR102676705B1/ko active Active
- 2016-04-29 JP JP2017556627A patent/JP7019422B2/ja active Active
- 2016-04-29 BR BR112017023269-3A patent/BR112017023269A2/en not_active Application Discontinuation
- 2016-04-29 CA CA2984200A patent/CA2984200C/en active Active
- 2016-04-29 CN CN201680039059.9A patent/CN108024541B/zh active Active
- 2016-04-29 EP EP16787290.2A patent/EP3294065A4/en active Pending
- 2016-04-29 MX MX2021005561A patent/MX393599B/es unknown
-
2017
- 2017-10-26 MX MX2021004881A patent/MX2021004881A/es unknown
- 2017-10-26 US US15/794,910 patent/US20180214393A1/en not_active Abandoned
- 2017-10-26 US US15/794,774 patent/US20180153828A1/en not_active Abandoned
- 2017-10-26 US US15/794,861 patent/US20180169101A1/en not_active Abandoned
- 2017-10-26 MX MX2021003389A patent/MX2021003389A/es unknown
-
2019
- 2019-08-20 US US16/545,859 patent/US20200046655A1/en not_active Abandoned
- 2019-09-24 US US16/580,914 patent/US11413258B2/en active Active
-
2020
- 2020-08-04 US US16/985,021 patent/US11819480B2/en active Active
-
2021
- 2021-03-25 JP JP2021052305A patent/JP7146992B2/ja active Active
- 2021-04-23 JP JP2021073337A patent/JP7262508B2/ja active Active
- 2021-10-25 US US17/510,050 patent/US12263141B2/en active Active
-
2022
- 2022-06-29 US US17/852,673 patent/US20220339126A1/en active Pending
- 2022-09-21 JP JP2022150560A patent/JP7516472B2/ja active Active
-
2023
- 2023-01-25 JP JP2023009598A patent/JP7696378B2/ja active Active
- 2023-09-12 US US18/367,103 patent/US20240099996A1/en not_active Abandoned
- 2023-10-24 IL IL307981A patent/IL307981B1/en unknown
- 2023-10-24 IL IL307983A patent/IL307983B1/en unknown
- 2023-11-16 US US18/511,036 patent/US20240091177A1/en not_active Abandoned
-
2024
- 2024-07-03 JP JP2024107407A patent/JP7745708B2/ja active Active
-
2025
- 2025-08-12 US US19/297,614 patent/US20250367140A1/en active Pending
- 2025-08-18 US US19/302,585 patent/US20250367141A1/en active Pending
- 2025-09-16 JP JP2025153179A patent/JP2025170141A/ja active Pending
- 2025-10-13 IL IL323926A patent/IL323926A/en unknown
- 2025-10-13 IL IL323924A patent/IL323924A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514549A5 (enExample) | ||
| JP2018518529A5 (enExample) | ||
| RU2017140676A (ru) | Способы лечения рака | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| ES2389809T3 (es) | Terapias anticancerosas | |
| JP2024516363A (ja) | リボシクリブ及びアムセネストラントを含む組み合わせ | |
| JP2024516795A (ja) | エベロリムスおよびアムセネストラントを含む組合せ物 | |
| JP2023550149A (ja) | アベマシクリブと６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸とを含む組み合わせ | |
| US20230129787A1 (en) | Methods for treating ovarian cancer | |
| JPWO2020118213A5 (enExample) | ||
| US20250275969A1 (en) | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| NZ737822B2 (en) | Methods of treating cancer | |
| NZ737819B2 (en) | Methods for treating cancer | |
| RU2021116084A (ru) | Способы лечения рака на моделях, имеющих мутации esr1 | |
| JPWO2020118202A5 (enExample) | ||
| RU2021116293A (ru) | Способы лечения устойчивого к ингибиторам cdk4/6 рака | |
| Tamborero Noguera et al. | Cancer bioMarkers database | |
| WO2016091167A1 (zh) | 抗肺鳞癌的喹啉衍生物 | |
| HK40006340B (en) | Rad1901 for use in treating ovarian cancer | |
| Holle et al. | Overview of Cancer Therapy | |
| MXPA06008954A (en) | Anti-cancer therapies |